Eat Less + Feel lighter

Tirzepatide

A dual GIP and GLP-1 receptor agonist that blocks cravings, slows digestion, and helps you get full sooner and stay full longer.

  • No Insurance Required

  • Ships From USA Pharmacy

  • Free Medical Consultation

  • Syringes Included

  • No Subscription Required

  • Licensed Provider

  • Licensed Pharmacy

  • HIPAA Compliant

  • LegitScript Certified

Overview

Pharmacology

Tirzepatide activates both GIP and GLP-1 receptors simultaneously, blocking cravings at the brain level while improving how your body processes food, fat, and blood sugar.

Mechanism of Action

Inhibits glucagon secretion from the pancreas, reducing excess glucose release from the liver, improves insulin sensitivity, and slows gastric emptying.

Injection

Subcutaneous injection administered once weekly.

Information presented here is for educational purposes only and not intended to replace or substitute guidance from a healthcare provider. Compounded products are not FDA-approved nor evaluated by the FDA for safety, efficacy, or quality.

Benefits

Appetite Regulation

Tirzepatide slows gastric emptying so food stays in your stomach longer, meaning you get full sooner and stay full longer. You naturally eat less without willpower or restriction.

Blocks Cravings

Acts directly on hunger and reward centers in the brain to shut down cravings, reducing the urge to snack, overeat, or seek high-calorie foods throughout the day.

Insulin Sensitivity

Improves how your cells respond to insulin, helping your body use glucose more efficiently, reducing fat storage and stabilizing energy levels throughout the day.

Gucagon Suppression

Inhibits excess glucagon release from the pancreas, reducing glucose output from the liver, preventing unnecessary glucose spikes, reducing fat accumulation, and supporting sustained long-term weight loss.

Individual results may vary. Benefits described are based on clinical and pharmacological evidence and do not constitute a guarantee of treatment outcomes. All treatment requires evaluation and approval by a licensed provider.

Molecular Pharmacology

Dual vs. Single Receptor Mechanism

Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist. Engaging both receptors simultaneously produces weight loss and metabolic improvements that exceed what GLP-1 agonism alone can achieve.

Dual Agonist
GIP-R GLP-1R
Tirzepatide
C₂₂₅H₃₄₈N₄₈O₆₈ · 4,813 Da
39-amino acid peptide · Weekly SubQ
GIP-R + GLP-1R dual agonism
2.5 mg → 15 mg · Weekly
GLP-1 Agonist
GLP-1R Only
Semaglutide
C₁₈₇H₂₉₁N₄₅O₅₉ · 4,113 Da
31-amino acid peptide · Weekly SubQ
GLP-1R agonism only
0.25 mg → 2.4 mg · Weekly
22.5%
Tirzepatide avg. body weight loss
(SURMOUNT-1 trial, 72 weeks)
14.9%
Semaglutide avg. body weight loss
(STEP-1 trial, 68 weeks)
+7.6%
Additional weight loss advantage
from dual receptor engagement
Receptor 1
GIP-R (Tirzepatide only)
GIP receptor activation in adipose tissue and pancreatic beta cells enhances insulin secretion in a glucose-dependent manner and drives fat cell remodeling. GIP also modulates central reward pathways, reducing food-seeking behavior through a mechanism distinct from GLP-1.
Receptor 2
GLP-1R (Both compounds)
GLP-1 receptor agonism slows gastric emptying, suppresses glucagon secretion, and reduces appetite via hypothalamic signaling. It also stimulates insulin release from pancreatic beta cells in response to glucose — producing significant reductions in post-meal blood sugar.
Synergy Effect
Dual Agonism Advantage
GIP and GLP-1 receptors operate through partially overlapping but non-identical intracellular pathways. Co-activation produces additive and in several tissues synergistic effects — particularly in adipose tissue, where GIP amplifies the fat-oxidizing effects of GLP-1 receptor activation.

Pharmacological Comparison

Effect Profile by Domain

Relative potency across six metabolic domains — showing where dual agonism outperforms GLP-1 monotherapy and where the mechanisms converge.

Tirzepatide (Dual GIP/GLP-1)
Semaglutide (GLP-1 only)
Radar Analysis
Metabolic Domain Coverage
Potency Index
Domain Intensity by Compound
BODY WEIGHT REDUCTION
Tirzepatide
96
Semaglutide
78
INSULIN SENSITIZATION
Tirzepatide
92
Semaglutide
72
APPETITE SUPPRESSION
Tirzepatide
90
Semaglutide
85
CARDIOVASCULAR
Tirzepatide
80
Semaglutide
74
Pharmacokinetics
Weekly Injection Cycle — Plasma Availability
Inject Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Tirzepatide
T½ ~5 days · Peak Day 1–3 · Sustained through Day 7
Semaglutide
T½ ~7 days · Peak Day 1–2 · Sustained through Day 7

Both compounds are dosed once weekly. Full clinical effect develops over 8–20 weeks of dose escalation.


Clinical Outcomes

What the Dual Mechanism Delivers

Six independent metabolic pathways engaged simultaneously — producing outcomes no single-receptor compound can replicate.

Superior Weight Loss
SURMOUNT-1 demonstrated 22.5% body weight reduction at 15 mg — the largest weight loss outcome ever recorded in a phase 3 obesity drug trial. GIP receptor engagement in adipose tissue drives fat oxidation beyond what GLP-1 alone produces.
Tirzepatide
Insulin Sensitization
GIP receptor activation in skeletal muscle and adipose tissue improves insulin signaling independent of weight loss. Tirzepatide produces greater reductions in fasting glucose, HbA1c, and HOMA-IR than semaglutide at comparable doses — a direct effect of dual receptor engagement.
Tirzepatide
Appetite & Satiety Control
GLP-1 receptor agonism suppresses appetite through hypothalamic signaling and delayed gastric emptying. GIP simultaneously modulates mesolimbic reward pathways, reducing food-seeking behavior through a distinct neural mechanism — together producing more durable appetite suppression.
TirzepatideSemaglutide
Adipose Tissue Remodeling
GIP receptor activation in fat tissue drives a metabolic shift from lipid storage toward fat oxidation — reducing visceral adipose tissue preferentially. This remodeling effect is unique to tirzepatide and is not produced by GLP-1 agonism alone, contributing to its superior body composition outcomes.
Tirzepatide
Cardiovascular Protection
Both compounds reduce major adverse cardiovascular events (MACE) in high-risk patients. Tirzepatide additionally improves blood pressure, triglycerides, and HDL cholesterol — cardiometabolic benefits that extend beyond weight loss via direct vascular and lipid-modulating effects.
TirzepatideSemaglutide
Lean Mass Preservation
Unlike older weight loss interventions, tirzepatide preserves a higher proportion of lean muscle mass during weight loss — critical for maintaining metabolic rate, functional strength, and long-term weight maintenance. Combined with resistance training, lean mass loss is minimal.
Tirzepatide
Prescription Required — Medical Supervision Mandatory. Compounded tirzepatide is available by prescription only following provider review. Contraindications include personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), prior serious hypersensitivity to tirzepatide, and Type 1 diabetes mellitus. Common side effects include nausea, vomiting, diarrhea, and constipation — typically mild and resolving with dose escalation. Not approved for use in patients under 18.

Simple. Medical.

Personalized.

Medical intake

Answer a few online questions about your health history, lifestyle, & goals. No clinic visits required.

Provider evaluation

A licensed medical provider reviews your intake to determine the safest, personalized treatment.

Personalized plan

Custom treatment plan built around your unique health needs, goals, medical history, & biology.

Ongoing support

Stay connected with your care team for follow-ups, adjustments, & expert answers 100% online.

FAQs

Does Tirzepatide require a prescription?

Yes. Tirzepatide is a compounded prescription medication available only pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation, medical intake, and provider evaluation are required before dispensing to confirm clinical suitability, screen for contraindications, and establish an individualized titration plan.

What are the possible side effects?

The most common side effects are gastrointestinal and occur most frequently during dose escalation — they include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. Most patients find these effects diminish as the body adjusts to each dose level. Injection site reactions including mild redness, swelling, or transient discomfort may also occur. Seek prompt medical attention for severe or persistent abdominal pain or any symptoms suggestive of pancreatitis. Report all side effects to your provider.

Who should not use Tirzepatide?

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). It is not appropriate for patients with known hypersensitivity to tirzepatide or any component of the formulation, those with a history of serious pancreatitis, severe gastroparesis, or significant gastrointestinal disorders. Patients with severe renal impairment or serious hepatic dysfunction require individualized provider assessment. This medication is contraindicated during pregnancy.

Are there any drug interactions?

Patients using insulin or sulfonylureas concurrently face an elevated risk of hypoglycemia, and dose adjustments of those agents are often required when Tirzepatide is initiated. Tirzepatide's gastric-emptying-slowing effect can delay absorption of orally administered medications including oral contraceptives and thyroid hormone, potentially affecting their clinical effectiveness. Patients on warfarin may need more frequent INR monitoring. Always provide a complete medication list to your provider before beginning treatment

Is Tirzepatide safe if I have a pre-existing medical condition?

Patients with a personal or family history of thyroid cancer or MEN2 must not use Tirzepatide. Those with type 1 diabetes, a history of pancreatitis, or significant gastrointestinal disorders require careful individualized evaluation. Patients with cardiovascular disease, hypertension, or significant renal or hepatic impairment can often be treated but require close provider monitoring. Your provider requires a complete medical history before prescribing and will determine whether Tirzepatide is appropriate for your specific health profile.

Contact Us

Text or Call

Hours

Monday–Saturday, 10am–8pm ET

Text or Call

Hours

Monday–Saturday, 10am–8pm ET

Start Your Journey

Ready to Reset

Your Metabolism?

Physician-supervised. Delivered to your door. No clinic visits required.

  • Licensed Provider

  • Licensed Pharmacy

  • HIPAA Compliant

  • LegitScript Certified

© 2026, Skinny Rich Shot®

[email protected]

text (323)-283-9219

638 1/2 N. Robertson Blvd, West Hollywood, CA 90069

Available in select U.S. states. Eligibility is determined by the provider. Compounded semaglutide and tirzepatide are not FDA-approved for weight loss. It is prescribed only when deemed medically appropriate by a licensed provider after review. Individual results vary significantly based on factors like adherence, diet, exercise, and health status. No guarantees of weight loss. GLP-1 medications like semaglutide may increase the risk of thyroid C-cell tumors based on animal studies; human risk is not confirmed. Services provided by licensed physicians/nurse practitioners in states served, e.g., CA, FL, and others, via telemedicine. Check your state's telemedicine laws. We prioritize your privacy and comply with HIPAA regulations for protected health information. Must be 18 or older.